Related Experiment Video

Updated: Jul 16, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.6K

Emergent HIV drug resistance in non-inferiority trials

Diego Ripamonti1, Maurizio Zazzi2

  • 1Infectious Diseases Unit, ASST Papa Giovanni XXIII Hospital, Bergamo 24127, Italy.

The Lancet. HIV
|September 15, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.2K

Related Experiment Videos

Last Updated: Jul 16, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.6K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.2K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

46.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

Articles linked to this work by shared authors, journal, and citation graph.

Narrative Review of Two-Drug Regimens in Modern HIV Care: Driving Innovation, Flexibility, and Quality of Life.

Infectious diseases and therapy·2026

Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.

AIDS (London, England)·2026

VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment.

Open forum infectious diseases·2026

HIV-1 Sub-subtype A6 Remains Susceptible to Second-Generation Integrase Inhibitors With Limited Emergence of Resistance in Vitro.

Open forum infectious diseases·2026

Increased in-hospital mortality in immunocompromised individuals hospitalized with COVID-19 during the global pandemic, a multinational cohort study in the EuCARE project.

The Journal of infectious diseases·2026

Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing.

The Journal of antimicrobial chemotherapy·2026

Metabolic dysfunction-associated steatotic liver disease in people living with HIV: a framework for integrated screening and care.

The lancet. HIV·2026

Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial.

The lancet. HIV·2026

Targeted point-of-care HIV testing at birth for newborns at high risk of vertical transmission in Botswana: a prospective cohort study.

The lancet. HIV·2026

Plasma dolutegravir exposure testing to identify people with HIV at highest risk for dolutegravir resistance (ITREMA-2): a two-centre, prospective implementation study in South Africa.

The lancet. HIV·2026

Epidemiology and management of HIV-2.

The lancet. HIV·2026

Global, regional, and national burden of HIV/AIDS, 1990-2023, with the estimated burden attributable to intimate partner violence and forecasted impacts of funding cuts through 2030: results from the Global Burden of Disease Study 2023.

The lancet. HIV·2026

Correction: Nitazoxanide mitigates methotrexate hepatotoxicity in rats: role in inhibiting apoptosis and regulating endoplasmic reticulum stress.

Frontiers in pharmacology·2026

Corrigendum to "Characterization of the tail current of Channelrhodopsin-2 variants" [Biochem. Biophys. Rep. 39 (2024) 101787].

Biochemistry and biophysics reports·2026

Predicting clinically significant medication errors: Development and validation of a risk stratification model using incident reporting data.

Frontiers in medicine·2026

Artificial intelligence in preclinical nonhuman primate xenotransplantation: bridging the gap from data complexity to clinical precision.

Clinical transplantation and research·2026

The efficacy and safety of microwave ablation in benign large thyroid nodules (≥4 cm).

European thyroid journal·2026

The Medicine Quality Monitoring Globe: A public health intelligence system for collecting and curating reports of substandard and falsified medical products from publicly available Internet news media.

PLOS digital health·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us